AVE9633 may be a potent cytotoxic chemotherapy for AML patients whose blasts express P-gp, especially older patients, and it may be beneficial in combination with the conventional anthracycline AML regimens, resistance to which is related to the expression of ABC proteins. Here, PGP is linked to acute myeloid leukemia.